Meet Agathe and Julien at the 2nd IMS public scientific meeting at the IPHC (Campus Cronenbourg) on 28th April 2022 ! They will present their experiences about the DDD challenge organized by the IMS and their strategy for the development of a new therapeutic tool against cancer stem-like cells ! https://ims.unistra.fr/journee-scientifique-de-lims/ |
Meet Ketty, Agathe and Julien at the Biotech Day at the ESBS on December 2nd 2021 ! Learn more on the next generation single-cell tools with the presentation of MicroOmix ! Ketty, our engineer will give you his feedback and his transition from public research to start-up ! Want to discover the DDD Challenge ? Agathe and Julien will present their experiences about this challenge organized by the IMS and their strategy for the development of a new therapeutic tool against cancer stem-like cells ! |
Congratulations to Alain who received 2 prices. The Seqens price of the French Academy of Science and the Berthelot medal for his contribution on the development of novel strategies in the use of chemical reactions in biological media for the manipulation of living systems ! The team is really proud of you for all these great achievements ! TOUTES NOS FELICITATIONS ALAIN ! |
We are happy to welcome Dr Abhaya K Mishra, a post-doc from the team of Prof. Jerome Waser at the LCSO, EPFL (Switzerland)! Drawing from the expertise of our two groups, he will test his compound in an effort to develop novel protein conjugation method! He will stay with us for a two-week period time! |
Our team is looking for a competent and highly motivated biological engineer to work on the development of biological methods for the study of new cleavable linkers ! Find more details in the descriptions :
![]()
|
Welcome to our new PhD student , Safae Mouftakhir (University of Grenoble-Alpes)! She is in collaboration with the team of Michael Ryckelynck (https://ibmc.cnrs.fr/laboratoire/arn/equipes/biologie-digitale-de-larn/)! Good luck! |
Do you want to learn more about our newest start-up MicroOmix ? In collaboration with the University of Strasbourg, we made a reporting video about the origin and the aim of the company ! You can watch this video in the following link : https://recherche.unistra.fr/actualites-recherche/actualites-de-la-recherche/microomix-de-la-recherche-a-la-start-up |
Our team is looking for a competent and highly motivated synthetic chemist for a PhD project in the field of microfluidics at the interface of chemistry and biology ! Find more details in the descriptions :
![]()
|
Our team, in partnership with Sanofi (Vitry-sur-Seine), is looking for a competent and highly motivated master student for a PhD position in the field of organic chemistry applied to protein bioconjugation ! Find more details in the descriptions : ![]()
|
Our team is looking for a competent and highly motivated synthetic chemist for a post-doctoral position in the field of organic chemistry applied to protein bioconjugation ! Find more details in the descriptions :
![]()
|
Our team is looking for a competent and highly motivated synthetic chemist for a PhD project in the field of organic chemistry applied to protein bioconjugation ! Find more details in the descriptions :
![]()
|
In the context of a project funded by the European Commission (European Training Network), our group and 8 other partners are recruiting 11 PhD students, to work at the interface of chemistry and biology, for the development of new targeted anti-cancer therapies.
Find more details in the description or on the website: http://tact-etn.eu ![]()
|
‘Targeted Anti-Cancer Therapies’ (TACT) is a ‘European Training Network’ (ETN) research project that received funding by the European Commission under the ‘Horizon 2020 research and innovation programme’ and the ‘Marie Skłodowska-Curie actions’. The TACT project results from the collaboration between six universities and three companies located in five different European countries and aims to train early-stage PhD students in the development of state-of-the-art targeted anti-cancer therapeutics.
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under the Marie Skłodowska Curie Action Grant Agreement No 859458. http://tact-etn.eu |
The BFC lab is proud to take part in the creation of the Strasbourg Interdisciplinary Drug Discovery and Development Institute (IMS) with Alain being its Innovation Director (INEdis)! |
Meet Charlotte at the Holtzheim library on december the 5th at 8 pm. She will give a talk on "Cancers: actual and future therapies". Charlotte donnera une conférence à la médiathèque d'Holtzheim le 5 décembre à 20 h. La conférence traitera du cancer et des thérapies actuelles et futures, et sera tout public. Venez nombreux ! |
![]()
![]()
|
We are looking for two highly motivated master students who wish to do their master project at the interface of chemistry and biology.
One project will aim to design new strain alkynes and then test their reactivity in SPAAC. The second project will imply the synthesis of unnatural retinoids to discover what the active form of vitamin A is in vivo; This project has already received a funding from the Agence Nationale de la Recherche for a PhD, which could be attributed to the student in case of fruitful results. You will find more details about the two internships in the following offers. |
![]()
![]()
|
|
BFC Group is proud to announce a new collaboration with Dr. W. Krewel (IGBMC - INSERM - UMR7104)
NEW APPROACH IN BIOORTHOGONAL CHEMISTRY FOR THE STUDY OF BIOACTIVE MOLECULES IN VIVO
Although recent developments in dedicated analysis technologies facilitate the identification and study of small bioactive molecules, researchers face difficulties with the scanty molecules, detection problems or instability of certain categories of molecules.
This project brings together various expertise in biology and chemistry to validate a new method of integrative multi-level analysis of small molecules in a complex biological environment. This method is based on a highly biospecific reaction, which we have recently demonstrated to be effective in targeting an exogenous molecule in vivo. We propose today to apply this new approach to small bioactive endogenous lipids using chemiospecific probes, thus determining metabolic fate, identifying relevant metabolic enzymes and receptors, and controlling bioavailability. The data obtained should validate existing knowledge and provide answers to the open questions of biology, while opening new avenues for questioning the physiology and pathology of biological processes. |
Dr. Wojciech Krezel
|
![]()
![]()
|
Tournoi de football de la chimie
Daniel Martina" 2018 Ambiance sportive, festive et amicale sous le soleil ! Mardi 5 juin sur le terrain du campus d’Illkirch, s’est déroulé le traditionnel tournoi de football réunissant cette année une douzaine d’équipes. L’équipe mixte UMR 7199/7200, motivée et sur entrainée, a brillé sur les terrains en terminant demi-finaliste. Bravo Guilhem, Mickael, Fabien, Nicolas, Sébastien, Lucie, Laure, Mickael, Fabien et Léo! |
Chemistry Football Tournament
"Daniel Martina" 2018 Sporty, festive and friendly atmosphere under the sun! Tuesday, June 5th, on the grounds of Illkirch campus, the traditional football tournament was held, with the participation this year of 12 teams. The motivated and over-trained mixed team UMR 7199/7200 shone on the field, conquering the semi-finals. Congrats to Guilhem, Mickael, Fabien, Nicolas, Sébastien, Lucie, Laure, Mickael, Fabien and Léo! |
![]()
|
[MEET US!]
|
When:
|
BioFIT is proud to host LabEx Medalis for this edition in Strasbourg. The Drug research center Medalis is a “Laboratory of Excellence” (Labex) created in July 2011 as part of the French program “Investments for the Future”. It is a member of “Initiatives of excellence” (IDEX) in the University of Strasbourg. The aim of the company is to develop innovative drugs for cancer or inflammation treatment. On the 28th of November will be held 3 conferences introduced by LabEx Medalis: – Session 1: Translational research at Medalis: From lab to biotech – Session 2: Early projects, early opportunity: Find your match – Session 3: Nature and nurture of an Academic drug discovery Center |
Registration is free but mandatory. |
![]()
|
BioCentury's weekly flagship publication provides analysis, interpretation and commentary on biopharma industry corporate performance, product discovery and development, emerging companies and technology, public policy, regulatory events and innovation and financial markets. (Source here)
|
22/06/17 - BFC group is looking for a Post-Doc (18 months) in the field of Bioconjugation and Antibody-Drug Conjugates.
![]()
25/07/17 The position has been filled |
20/06/17 - BFC's and IGBMC's last discovery is now available on Nature Communications and on the official CNRS site!
|
Click on the icons to visit the official pages of CNRS!
|
Neutraliser un médicament dans l’organisme pour stopper ses effets secondaires @unistra @NatureComms #sante https://t.co/wCjuXy3o9P pic.twitter.com/UCDU8dKobw
— Chimie au CNRS (@INC_CNRS) 20 giugno 2017
MPX: Fighting Cancer at the Unique Cell ScaleHow to fight cancer cells more effectively? Three laboratories have put their expertise together to provide a new way of answering this question. The Laboratory of Design and Application of Bioactive Molecules (UMR 7199), the Laboratory Architecture and Reactivity of RNA, and the Laboratory Targeted Therapies of the Microenvironment Tumor, have joined forces to give birth to the MPX project, a new development in microfluidics. Ketty Pernod and Sylvain Ursuegui, the two promoters of the project, explain their approach in this short video.
|
Welcome!Welcome to Guilhem Chaubet who joined BFC group in January 2017 as CNRS Researcher to investigate new site-specific bioconjugation strategies.
Guilhem was born in Avignon, France, and completed his undergraduate and PhD degrees in Montpellier in the group of Prof. Jean Martinez. His research activities focused on ring-contraction reactions and their use for the synthesis of organized edifices, such as foldamers. He then started a postdoc in the Ed Anderson group at the University of Oxford where he worked on the total synthesis of rubriflordilactone, on the synthesis of new phosphoramidite ligands for rhodium-catalysis and on the development of a new approach to access heteroaromatics using palladium-catalysis.
|